Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Undesirable gut bacteria" refers collectively to bacterial species in the intestinal microbiome that, when overgrown or unbalanced, are associated with disease states, including inflammation, metabolic disease, neurodegenerative disorders, and infections. This is not a specific molecular target but a descriptive state of microbiome imbalance (dysbiosis), in which pathogenic or pro-inflammatory bacteria predominate over beneficial commensals, disrupting normal gut and systemic functions. Therapeutic approaches are focused on modulating the overall microbiota composition rather than targeting a discrete protein or receptor.
Suppression or elimination of undesirable species through antibiotics; Restoration of microbiome balance (e.g., by FMT or probiotics); Modulation of bacterial metabolites (e.g., inhibition of TMA production to reduce TMAO-linked atherogenesis)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Undesirable gut bacteria.